Imunon IMNN 深 沪
等待开盘 10-03 09:30:00 美东时间
1.37
+0.050
+3.79%
华盛通- 最 高1.38
- 今 开1.35
- 成交量 7.22万股
- 最 低 1.29
- 昨 收 1.32
- 总市值 768.76万
- 52周最高 5.29
- 市盈率 静 --
- 换手率 1.29%
- 52周最低 1.26
- 委 比 -39.58%
- 总股本 561.14万
- 历史最高 25857.3851
- 量 比 0.77
- 振 幅 6.82%
- 历史最低 1.26
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Imunon Introduces Series B Preferred to Restructure Debt
Imunon ( ($IMNN) ) has issued an update. On June 2, 2026, Imunon entered into a...
09-29 20:29
IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis L...
09-24 20:10
IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001's differentia...
09-22 20:10
Imunon Q2 EPS $(0.54) Beats $(0.93) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per share from the same period last year.
08-11 20:02
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study
Clinical-stage biotechnology firm Imunon Inc. (NASDAQ:IMNN) on Thursday announced an update on its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patients. The company reported site activation and patient enrollment speeds that significantly outpace or...
07-30 20:30
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial. MRD refers to the small number of cancer cells that remain in the body during or after treatment. The data showed that patients receiving IMNN-001 along...
07-21 20:30
IMUNON Receives Independent Data Monitoring Committee Recommended Continuation Of Pivotal Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Neoadjuvant And Adjuvant Chemotherapy In Women With Newly Diagnosed Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with ...
06-23 20:03
IMUNON Enters Into Definitive Agreements For $10M In Preferred Stock And Secured Notes
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 millionUniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATION 3 Study of
06-04 20:04
Imunon Reports Q1 2026 Results: Full Earnings Call Transcript
Imunon (NASDAQ:IMNN) released first-quarter financial results and hosted an ear...
05-12 23:54
Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per share from the same
05-12 20:01
